Vanda Pharmaceuticals Inc. (VNDA) Given Average Rating of “Buy” by Analysts
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has received a consensus rating of “Buy” from the ten research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $21.75.
Several research analysts recently issued reports on the company. Jefferies Group LLC reissued a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research note on Thursday, May 25th. Oppenheimer Holdings, Inc. assumed coverage on Vanda Pharmaceuticals in a research note on Wednesday, April 12th. They issued an “outperform” rating and a $21.00 price objective on the stock. TheStreet raised Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Friday, May 12th. Zacks Investment Research cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, June 7th. Finally, CIBC reaffirmed an “outperform” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th.
A number of hedge funds have recently made changes to their positions in the stock. Virginia Retirement Systems ET AL bought a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at about $193,000. Capital Fund Management S.A. bought a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at about $195,000. AQR Capital Management LLC bought a new stake in shares of Vanda Pharmaceuticals during the fourth quarter valued at about $223,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at about $196,000. Finally, Algert Global LLC boosted its stake in shares of Vanda Pharmaceuticals by 11.8% in the first quarter. Algert Global LLC now owns 18,223 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 1,927 shares during the period. 92.51% of the stock is currently owned by institutional investors and hedge funds.
Vanda Pharmaceuticals (VNDA) traded up 0.92% on Friday, hitting $16.45. The stock had a trading volume of 67,514 shares. The firm’s market capitalization is $732.88 million. The stock’s 50-day moving average is $15.39 and its 200 day moving average is $14.54. Vanda Pharmaceuticals has a 1-year low of $10.98 and a 1-year high of $18.00.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.04. Vanda Pharmaceuticals had a negative return on equity of 10.42% and a negative net margin of 8.85%. The firm had revenue of $37.42 million during the quarter, compared to the consensus estimate of $38.35 million. On average, equities research analysts predict that Vanda Pharmaceuticals will post ($0.70) earnings per share for the current fiscal year.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.